LYRICA CR CV
Generic Name and Formulations:
Pregabalin 82.5mg, 165mg, 330mg; ext-rel tabs.
Indications for LYRICA CR:
Neuropathic pain associated with diabetic peripheral neuropathy (DPN). Postherpetic neuralgia (PHN).
Swallow whole. Take once daily after evening meal. DPN: initially 165mg daily, may increase to max 330mg/day within 1 week. PHN: initially 165mg daily, may increase to 330mg daily within 1 week; max 660mg/day if insufficient relief after 2–4wks. Conversion from Lyrica capsules, oral soln: see full labeling. For all: renal impairment (CrCl 30–60mL/min): reduce dose (see full labeling); (CrCl <30mL/min or hemodialysis): dose with Lyrica.
Avoid abrupt cessation (taper over ≥1 week). Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. CHF. Ocular conditions. Diabetes (monitor skin integrity). Suicidal tendencies (monitor). Pregnancy. Nursing mothers: not recommended.
Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones. Increased risk of angioedema with concomitant ACEIs.
Alpha-2 delta ligand.
Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal (primarily difficulty with concentration/attention), infection, asthenia, paresthesias, headache, fatigue; elevated creatine kinase, decreased platelets, arrhythmias (PR prolongation), male-mediated teratogenicity; may be tumorigenic.
Register patients in North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334.
Caps—90; CR tabs—30; Soln—16oz
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Rectal Cancer: Adjuvant Chemotherapy May Improve OS After pCR
- Breast Cancer: Determining the Best Diet for Disease Prevention
- Hormone Therapy for Breast Cancer May Cause Diabetes
- Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers
- Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma